TuHURA Biosciences, Inc. | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Headlines Articles Press releases TuHURA Biosciences, Inc.

Home
Companies
TuHURA Biosciences, Inc.

BRIEF

published on 10/23/2024 at 14:35, 28 days 23 hours ago

TuHURA Biosciences (Nasdaq: HURA) Presents at Maxim Healthcare Virtual Summit

TuHURA Biosciences Immune-oncology IFx-2.0 Checkpoint Inhibitors Maxim Healthcare Virtual Summit
PRESS RELEASE

published on 10/23/2024 at 14:30, 28 days 23 hours ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TuHURA Biosciences, Inc. participated in the 2024 Maxim Healthcare Virtual Summit, sharing insights on overcoming resistance to cancer immunotherapy. The company is developing innovative technologies for immuno-oncology

TuHURA Biosciences Immune-oncology Resistance To Cancer Immunotherapy Novel Technologies Phase 3 Registration
BRIEF

published on 10/22/2024 at 15:05, 29 days 22 hours ago

TuHURA Biosciences Set to Present at Virtual Investor Event

TuHURA Biosciences Virtual Investor Event Immune-oncology Phase 3 Trials Cancer Resistance
PRESS RELEASE

published on 10/22/2024 at 15:00, 29 days 23 hours ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
TuHURA Biosciences, Inc. to present at Virtual Investor New to the Street Event featuring Dr. Jim Bianco discussing company's outlook and technologies for cancer immunotherapy

TuHURA Biosciences Phase 3 Trial Virtual Investor Event Cancer Immunotherapy Dr. Jim Bianco
BRIEF

published on 10/17/2024 at 21:38, 1 month 3 days ago

TuHURA Biosciences and Kintara Therapeutics Complete Merger

Merger TuHURA Biosciences Phase 3 Trial Cancer Immunotherapy NASDAQ Trading
PRESS RELEASE

published on 10/17/2024 at 21:33, 1 month 3 days ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics
TuHURA Biosciences, Inc. completes merger with Kintara Therapeutics, focusing on cancer immunotherapy technologies. Phase 3 trial in 2025 under SPA agreement with FDA

Merger TuHURA Biosciences FDA Agreement Immunotherapy Phase 3 Trial
BRIEF

published on 08/19/2024 at 15:05, 3 months 1 day ago

Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial

Oncology Clinical Trial TuHURA Biosciences KVA12123 Kineta Inc.
PRESS RELEASE

published on 08/19/2024 at 15:00, 3 months 1 day ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta reopens enrollment for VISTA-101 clinical trial with KVA12123 antibody. Positive results at AACR 2024. TuHURA and Kineta join forces. Acquisition pending. Kintara merger progresses

Merger TuHURA Kineta KVA12123 VISTA-101
BRIEF

published on 07/08/2024 at 12:35, 4 months 13 days ago

TuHURA Biosciences Secures Exclusive Rights for Kineta’s KVA12123 Checkpoint Inhibitor

TuHURA Keytruda Kineta Checkpoint Inhibitor VISTA
PRESS RELEASE

published on 07/08/2024 at 12:30, 4 months 13 days ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
TuHURA Biosciences and Kintara Therapeutics announce an Exclusivity Agreement for potential acquisition of KVA12123 anti-VISTA antibody. KVA12123 aims to reverse VISTA immune suppression and enhance tumor immunity

TuHURA Biosciences Immunotherapy Kintara Therapeutics KVA12123 VISTA Antibody

Accesswire

Published on 11/21/2024 at 13:30, 32 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 32 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 47 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 27 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 47 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 55 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 2 hours 2 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 42 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 17 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 17 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE